Searle & CO. Purchases 5,332 Shares of Eli Lilly and Company (NYSE:LLY)

Searle & CO. raised its stake in shares of Eli Lilly and Company (NYSE:LLY) by 533.2% during the 4th quarter, Holdings Channel.com reports. The fund owned 6,332 shares of the company’s stock after purchasing an additional 5,332 shares during the quarter. Eli Lilly and Company makes up approximately 1.0% of Searle & CO.’s portfolio, making the stock its 25th largest holding. Searle & CO.’s holdings in Eli Lilly and Company were worth $3,691,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. Vicus Capital lifted its stake in shares of Eli Lilly and Company by 78.6% in the 3rd quarter. Vicus Capital now owns 977 shares of the company’s stock worth $525,000 after purchasing an additional 430 shares during the period. Callahan Advisors LLC lifted its stake in shares of Eli Lilly and Company by 655.2% in the 3rd quarter. Callahan Advisors LLC now owns 7,779 shares of the company’s stock worth $4,178,000 after purchasing an additional 6,749 shares during the period. Live Oak Private Wealth LLC lifted its stake in shares of Eli Lilly and Company by 2.3% in the 3rd quarter. Live Oak Private Wealth LLC now owns 1,809 shares of the company’s stock worth $972,000 after purchasing an additional 40 shares during the period. Kingswood Wealth Advisors LLC lifted its stake in shares of Eli Lilly and Company by 102.9% in the 3rd quarter. Kingswood Wealth Advisors LLC now owns 3,907 shares of the company’s stock worth $2,099,000 after purchasing an additional 1,981 shares during the period. Finally, Xponance Inc. increased its holdings in Eli Lilly and Company by 0.3% in the 3rd quarter. Xponance Inc. now owns 189,291 shares of the company’s stock worth $101,674,000 after acquiring an additional 590 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on LLY shares. JPMorgan Chase & Co. increased their price objective on shares of Eli Lilly and Company from $850.00 to $900.00 and gave the company an “overweight” rating in a report on Wednesday. Truist Financial raised their price target on Eli Lilly and Company from $850.00 to $892.00 and gave the stock a “buy” rating in a research report on Wednesday. Wells Fargo & Company lifted their target price on Eli Lilly and Company from $700.00 to $825.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 6th. Barclays lifted their target price on Eli Lilly and Company from $680.00 to $810.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 7th. Finally, Bank of America lifted their target price on Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a “buy” rating in a research note on Friday, March 1st. Three investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. Based on data from MarketBeat.com, Eli Lilly and Company has a consensus rating of “Moderate Buy” and an average target price of $742.95.

Eli Lilly and Company Stock Down 0.6 %

Shares of LLY traded down $4.35 during mid-day trading on Wednesday, reaching $776.75. The company’s stock had a trading volume of 2,762,349 shares, compared to its average volume of 3,067,435. Eli Lilly and Company has a 12-month low of $399.26 and a 12-month high of $800.78. The stock has a market cap of $738.04 billion, a PE ratio of 133.47, a price-to-earnings-growth ratio of 1.61 and a beta of 0.34. The company has a debt-to-equity ratio of 1.69, a current ratio of 0.94 and a quick ratio of 0.73. The company’s 50 day moving average is $761.41 and its 200 day moving average is $669.21.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Tuesday, April 30th. The company reported $2.58 EPS for the quarter, beating analysts’ consensus estimates of $2.53 by $0.05. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The business had revenue of $8.77 billion for the quarter, compared to the consensus estimate of $8.94 billion. During the same quarter in the prior year, the business posted $1.62 EPS. The business’s revenue for the quarter was up 26.0% on a year-over-year basis. Equities analysts anticipate that Eli Lilly and Company will post 12.51 EPS for the current fiscal year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.